Pacira Pharmaceuticals (PCRX) Stock Rating Reaffirmed by JPMorgan Chase & Co.

Pacira Pharmaceuticals (NASDAQ:PCRX)‘s stock had its “hold” rating reiterated by investment analysts at JPMorgan Chase & Co. in a research report issued on Thursday.

A number of other research firms have also issued reports on PCRX. Mizuho lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $53.00 to $44.00 in a research note on Wednesday, November 29th. Royal Bank of Canada set a $54.00 target price on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Canaccord Genuity set a $46.00 target price on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Leerink Swann assumed coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday. They set a “market perform” rating and a $46.00 target price for the company. Finally, BidaskClub raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $49.00.

Pacira Pharmaceuticals (PCRX) opened at $42.45 on Thursday. Pacira Pharmaceuticals has a fifty-two week low of $29.81 and a fifty-two week high of $58.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24. The company has a market cap of $1,720.00, a PE ratio of -32.40 and a beta of 2.20.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The business had revenue of $67.30 million during the quarter, compared to analyst estimates of $68.99 million. During the same period in the previous year, the business posted $0.20 EPS. The company’s quarterly revenue was down 1.6% on a year-over-year basis. analysts anticipate that Pacira Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

In other news, CEO David M. Stack sold 58,885 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total value of $2,257,650.90. Following the completion of the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at approximately $6,102,347.76. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kristen Marie Williams sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief accounting officer now directly owns 23,455 shares of the company’s stock, valued at $938,200. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 70,075 shares of company stock valued at $2,707,452. Company insiders own 6.60% of the company’s stock.

Several large investors have recently modified their holdings of the company. Principal Financial Group Inc. lifted its stake in shares of Pacira Pharmaceuticals by 5.2% in the 2nd quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock worth $261,000 after acquiring an additional 270 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Pacira Pharmaceuticals by 9.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after purchasing an additional 302 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Pacira Pharmaceuticals by 12.7% in the 2nd quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock worth $240,000 after purchasing an additional 566 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Pacira Pharmaceuticals by 5.3% in the 2nd quarter. Legal & General Group Plc now owns 12,985 shares of the company’s stock worth $620,000 after purchasing an additional 653 shares in the last quarter. Finally, California Public Employees Retirement System raised its holdings in shares of Pacira Pharmaceuticals by 2.2% in the 2nd quarter. California Public Employees Retirement System now owns 64,700 shares of the company’s stock worth $3,086,000 after purchasing an additional 1,400 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/01/06/pacira-pharmaceuticals-pcrx-stock-rating-reaffirmed-by-jpmorgan-chase-co.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply